Please assess the completion status of the following clinical trial:

Trial Title: Impact of Antiretroviral Treatment on Pharmacokinetics and Pharmacodynamics of Thienopyridines in Healthy Volunteers and HIV Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males \>18 years~* Understanding of French language and able to give an inform consent~* Anti-HIV therapy with ritonavir or cobicistat (for HIV group)~* Stable antiretroviral treatment since at least 2 weeks (for HIV group)~* Viremia \<100 copies/ml (for HIV group)~Exclusion Criteria:~* renal failure: calculated creatinine Clearance (cockcroft) \< 50ml/min~* hepatic impairment (ASAT, ALAT, bilirubin, gamma-GT more than 2-fold increase)~* smoker \>1 pack/day~* hypersensitivity to any of the drugs used~* intake of any drug or particular food (grapefruit) that can affect CYP activities inhibitors (in the last 10 days before the start of the study or 4 half-life after the last intake)~* pathologies or drugs associated with an increased bleeding risk such as aspirin, non-steroidal anti-inflammatory drugs, steroids and serotonin reuptake inhibitors (in the last 10 days before the start of the study or 4 half-life after the last intake)~* bleeding familial history or antecedent or haemorrhagic disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- HIV clopidogrel (Type: EXPERIMENTAL): clopidogrel 300 mg single dose oral route
- HIV prasugrel (Type: EXPERIMENTAL): prasugrel 60 mg single dose oral route
- Control clopidogrel (Type: ACTIVE_COMPARATOR): clopidogrel 300 mg single dose oral route
- Control prasugrel (Type: ACTIVE_COMPARATOR): prasugrel 60 mg single dose oral route

Based on this trial design, predict the completion outcome and termination type (if applicable).